Tenax Therapeutics (TENX) announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction. She served most recently as Interim Head, Clinical Development Operations with Noema Pharma.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: